Linezolid surveillance program results for 2008 (LEADER Program for 2008)

Diagnostic Microbiology and Infectious Disease

Volumn 65, Issue 4, 2009, Pages 392-403

  Farrell, David J ^a   Mendes, Rodrigo E ^a   Ross, James E ^a   Jones, Ronald N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cfr; LEADER; Linezolid; Oxazolidinones; Resistance; Target mutations

Indexed keywords

CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; OXACILLIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BETA HEMOLYTIC STREPTOCOCCUS; BROTH DILUTION; CLINICAL EFFECTIVENESS; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MONITORING; DRUG POTENCY; DRUG SURVEILLANCE PROGRAM; ENTEROCOCCUS; ENTEROCOCCUS FAECIUM; GENE MUTATION; GENOTYPE; HEALTH PROGRAM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PLASMID; PREVALENCE; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; RIBOSOME; SENSITIVITY ANALYSIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE; TREND STUDY; UNITED STATES;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; PREVALENCE; UNITED STATES;

EID: 71549153471     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2009.10.011     Document Type: Article

References (59)

1. Adembri C., Fallani S., Cassetta M.I., Arrigucci S., Ottaviano A., Pecile P., Mazzei T., De Gaudio R., and Novelli A. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int. J. Antimicrob. Agents 31 (2008) 122-129
2. Arias C.A., Vallejo M., Reyes J., Panesso D., Moreno J., Castaneda E., Villegas M.V., Murray B.E., and Quinn J.P. Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23S rRNA methyltransferase. J. Clin. Microbiol. 46 (2008) 892-896
3. Ballow C.H., Jones R.N., and Biedenbach D.J. A multicenter evaluation of linezolid antimicrobial activity in North America. Diagn. Microbiol. Infect. Dis. 43 (2002) 75-83
4. Besier S., Ludwig A., Zander J., Brade V., and Wichelhaus T.A. Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances. Antimicrob. Agents Chemother. 52 (2008) 1570-1572
5. Boak L.M., Li J., Rayner C.R., and Nation R.L. Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model. Antimicrob. Agents Chemother. 51 (2007) 1287-1292
6. Bonilla H., Quinn J.P., Siedel J., Schmidt H., Lescoe M., et al. Multi-city outbreak of linezolid resistant Staphylococcus epidermidis associated with clonal spread of a cfr containing strain. ICAAC (2009) C2-131 abstract
7. Brickner S.J. Oxazolidinone antibacterial agents. Curr. Pharmacol. Design 2 (1996) 175-194
8. Clinical and Laboratory Standards Institute CLSI. Performance standards for antimicrobial susceptibility testing: 18th informational supplement (M100-S18) (2008), CLSI, Wayne, PA
9. Clinical and Laboratory Standards Institute CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-eight edition, M07-A8 (2009), CLSI, Wayne, PA
10. Clinical and Laboratory Standards Institute CLSI. Performance standards for antimicrobial susceptibility testing: 19th informational supplement, M100-S19 (2009), CLSI, Wayne, PA
11. Clinical and Laboratory Standards Institute CLSI. Performance standards for antimicrobial disk susceptibility tests; approved standard-tenth edition, M02-A10 (2009), CLSI, Wayne, PA
12. Diekema D.J., and Jones R.N. Oxazolidinone antibiotics. Lancet 358 (2001) 1975-1982
13. Dobbs T.E., Patel M., Waites K.B., Moser S.A., Stamm A.M., and Hoesley C.J. Nosocomial spread of Enterococcus faecium resistant to vancomycin and linezolid in a tertiary care medical center. J. Clin. Microbiol. 44 (2006) 3368-3370
14. Draghi D.C., Sheehan D.J., Hogan P., and Sahm D.F. In vitro activity of linezolid against key gram-positive organisms isolated in the United States: Results of the LEADER 2004 surveillance program. Antimicrob. Agents Chemother. 49 (2005) 5024-5032
15. Draghi D.C., Sheehan D.J., Hogan P., and Sahm D.F. Current antimicrobial resistance profiles among methicillin-resistant Staphylococcus aureus encountered in the outpatient setting. Diagn. Microbiol. Infect. Dis. 55 (2006) 129-133
16. Ford C.W., Zurenko G.E., and Barbachyn M.R. The discovery of linezolid, the first oxazolidinone antibacterial agent. Curr. Drug Targets Infect. Disord. 1 (2001) 181-199
17. Gales A.C., Sader H.S., Andrade S.S., Lutz L., Machado A., and Barth A.L. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int. J. Antimicrob. Agents 27 (2006) 300-302
18. Gómez-Gil R., Romero-Gómez M.P., García-Arias A., Ubeda M.G., Busselo M.S., Cisterna R., Gutiérrez-Altés A., and Mingorance J. Nosocomial outbreak of linezolid-resistant Enterococcus faecalis infection in a tertiary care hospital. Diagn. Microbiol. Infect. Dis. (2009) [Epub ahead of print]
19. Gonzales R.D., Schreckenberger P.C., Graham M.B., Kelkar S., DenBesten K., and Quinn J.P. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357 (2001) 1179
20. Ippolito J.A., Kanyo Z.F., Wang D., Franceschi F.J., Moore P.B., Steitz T.A., and Duffy E.M. Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. J. Med. Chem. 51 (2008) 3353-3356
21. Jones R.N., Ballow C.H., and Biedenbach D.J. Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States. Diagn. Microbiol. Infect. Dis. 40 (2001) 59-66
22. Jones R.N., Della-Latta P., Lee L.V., and Biedenbach D.J. Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program. Diagn. Microbiol. Infect. Dis. 42 (2002) 137-139
23. Jones R.N., Fritsche T.R., Sader H.S., and Ross J.E. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). Diagn. Microbiol. Infect. Dis. 59 (2007) 309-317
24. Jones R.N., Stilwell M.G., Hogan P.A., and Sheehan D.J. Activity of linezolid tested against uncommonly isolated Gram-positive organisms (3,251 strains): report from the SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother. 51 (2007) 1491-1493
25. Jones R.N., Ross J.E., Castanheira M., and Mendes R.E. United States resistance surveillance results for linezolid (LEADER Program for 2007). Diagn. Microbiol. Infect. Dis. 62 (2008) 416-426
26. Jones R.N., Moet G.J., Sader H.S., Mendes R.E., and Castanheira M. TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens. J. Antimicrob. Therapy. 63 (2009) 716-720
27. Kainer M.A., Devasia R.A., Jones T.F., Simmons B.P., Melton K., Chow S., Broyles J., Moore K.L., Craig A.S., and Schaffner W. Response to emerging infection leading to outbreak of linezolid-resistant enterococci. Emerg. Infect. Dis. 13 (2007) 1024-1030
28. Kehrenberg C., and Schwarz S. Distribution of florfenicol resistance genes fexA and cfr among chloramphenicol-resistant Staphylococcus isolates. Antimicrob. Agents Chemother. 50 (2006) 1156-1163
29. Kehrenberg C., Schwarz S., Jacobsen L., Hansen L.H., and Vester B. A new mechanism for chloramphenicol, florfenicol and clindamycin resistance: methylation of 23S ribosomal RNA at A2503. Mol. Microbiol. 57 (2005) 1064-1073
30. Kehrenberg C., Aarestrup F.M., and Schwarz S. IS21-558 insertion sequences are involved in the mobility of the multiresistance gene cfr. Antimicrob. Agents Chemother. 51 (2007) 483-487
31. Kelly S., Collins J., Maguire M., Gowing C., Flanagan M., Donnelly M., and Murphy P.G. An outbreak of colonization with linezolid-resistant Staphylococcus epidermidis in an intensive therapy unit. J. Antimicrob. Chemother. 61 (2008) 901-907
32. Livermore D.M., Mushtaq S., Warner M., and Woodford N. Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant enterococci. J. Antimicrob. Chemother. 63 (2009) 713-715
33. Long K.S., Poehlsgaard J., Kehrenberg C., Schwarz S., and Vester B. The Cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimicrob. Agents Chemother. 50 (2006) 2500-2505
34. Marshall S.H., Donskey C.J., Hutton-Thomas R., Salata R.A., and Rice L.B. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob. Agents Chemother. 46 (2002) 3334-3336
35. McCollum M., Sorensen S.V., and Liu L.Z. A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients. Clin. Ther. 29 (2007) 469-477
36. McKinnon P.S., Carter C.T., Girase P.G., Liu L.Z., and Carmeli Y. The economic effect of oral linezolid versus intravenous vancomycin in the outpatient setting: the payer perspective. Manag. Care Interface 20 (2007) 23-34
37. Mendes R.E., Deshpande L.M., Castanheira M., DiPersio J., Saubolle M.A., and Jones R.N. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob. Agents Chemother. 52 (2008) 2244-2246
38. Mutnick A.H., Enne V., and Jones R.N. Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program. Ann. Pharmacother. 37 (2003) 769-774
39. Nasraway S.A., Shorr A.F., Kuter D.J., O'Grady N., Le V.H., and Cammarata S.K. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin. Infect. Dis. 37 (2003) 1609-1616
40. Pai M.P., Rodvold K.A., Schreckenberger P.C., Gonzales R.D., Petrolatti J.M., and Quinn J.P. Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium. Clin. Infect. Dis. 35 (2002) 1269-1272
41. Pillar C.M., Draghi D.C., Sheehan D.J., and Sahm D.F. Prevalence of multidrug-resistant, methicillin-resistant Staphylococcus aureus in the United States: findings of the stratified analysis of the 2004 to 2005 LEADER Surveillance Programs. Diagn. Microbiol. Infect. Dis. 60 (2008) 221-224
42. Potoski B.A., Adams J., Clarke L., Shutt K., Linden P.K., Baxter C., Pasculle A.W., Capitano B., Peleg A.Y., Szabo D., and Paterson D.L. Epidemiological profile of linezolid-resistant coagulase-negative staphylococci. Clin. Infect. Dis. 43 (2006) 165-171
43. Prystowsky J., Siddiqui F., Chosay J., Shinabarger D.L., Millichap J., Peterson L.R., and Noskin G.A. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 45 (2001) 2154-2156
44. Quinn J.P., Bonilla H., Huband M.D., Siedel J., Schmidt H., Lescoe M., McCurdy S.P., and Lemmon M.M. Identification and characterization of a linezolid-resistant, cfr containing Staphylococcus aureus strain during a clonal outbreak of linezolid-R coagulase negative staphylococci. ICAAC (2009) C2-134 abstract
45. Schwarz S., Werckenthin C., and Kehrenberg C. Identification of a plasmid-borne chloramphenicol-florfenicol resistance gene in Staphylococcus sciuri. Antimicrob. Agents Chemother. 44 (2000) 2530-2533
46. Shaw K.J., Poppe S., Schaadt R., Brown-Driver V., Finn J., Pillar C.J., Shinabarger D., and Zurenko G. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob. Agents Chemother. 52 (2008) 4442-4447
47. Shinabarger D. Mechanism of action of the oxazolidinone antibibacterial agents. Expert Opin. Investig. Drugs 8 (1999) 1195-1202
48. Shorr A.F., Kunkel M.J., and Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J. Antimicrob. Chemother. 56 (2005) 923-929
49. Spellberg B., Yoo T., and Bayer A.S. Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6. J. Antimicrob. Chemother. 54 (2004) 832-835
50. Stevens D.L., Herr D., Lampiris H., Hunt J.L., Batts D.H., and Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 34 (2002) 1481-1490
51. Toh S.M., Xiong L., Arias C.A., Villegas M.V., Lolans K., Quinn J., and Mankin A.S. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol. Microbiol. 64 (2007) 1506-1514
52. Tsiodras S., Gold H.S., Sakoulas G., Eliopoulos G.M., Wennersten C., Venkataraman L., Moellering R.C., and Ferraro M.J. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358 (2001) 207-208
53. Weigelt J., Itani K., Stevens D., Lau W., Dryden M., and Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 49 (2005) 2260-2266
54. Wilson P., Andrews J.A., Charlesworth R., Walesby R., Singer M., Farrell D.J., and Robbins M. Linezolid resistance in clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother. 51 (2003) 186-188
55. Wolter N., Smith A.M., Farrell D.J., Schaffner W., Moore M., Whitney C.G., Jorgensen J.H., and Klugman K.P. Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus. Antimicrob. Agents Chemother. 49 (2005) 3554-3557
56. Wunderink R.G., Cammarata S.K., Oliphant T.H., and Kollef M.H. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin. Ther. 25 (2003) 980-992
57. Wunderink R.G., Rello J., Cammarata S.K., Croos-Dabrera R.V., and Kollef M.H. Linezolid vs vancomycin: Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124 (2003) 1789-1797
58. Zurenko G.E., Yagi B.H., Schaadt R.D., Allison J.W., Kilburn J.O., Glickman S.E., Hutchinson D.K., Barbachyn M.R., and Brickner S.J. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob. Agents Chemother. 40 (1996) 839-845
59. Zyvox Package Insert. Pfizer. Available at (2004). http://www.pfizer.com/pfizer/download/uspi_zyvox.pdf